PEN — Penumbra, Inc.
$320.91
+$0.14 (+0.04%)
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Market Cap
$12.65B
Forward P/E
52.0x
52-Week Range
N/A
PEN Price History
Revenue vs. Net Income
$1.4B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$175M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
12.6%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.6x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
4.5%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.1%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
